<DOC>
	<DOC>NCT02406781</DOC>
	<brief_summary>This is a multicenter study assessing efficacy of the MK 3475 (Pembrolizumab) in combination with metronomic cyclophosphamide in patients with advanced sarcomas.</brief_summary>
	<brief_title>Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial</brief_title>
	<detailed_description>This is a phase 2 trial with 5 strata : - Leiomyosarcoma : 33 patients - Undifferentiated sarcoma : 33 patients - Sarcomas others : 33 patients - Osteosarcoma : 33 patients - GIST : 31 patients</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>1. Histology : Leiomyosarcoma, or UPS, or other sarcoma, or GIST or osteosarcoma, histologically confirmed by central review 2. Advanced non resectable / metastatic disease 3. Documented progression according to RECIST criteria. Progression on the last line of treatment should be confirmed by central review with two radiological assessments identical obtained at less than 6 months interval within the 12 months before inclusion 4. For stratum 5, documented disease progression according to RECIST criteria after the first line imatinib and second line sunitinib 5. Have provided tissue from an archival tissue sample obtained on metastasis or on locally advanced disease, or newly obtained core or excisional biopsy of a tumor lesion 6. For strata 1, 2 and 3: no more of four previous lines of systemic therapy for metastatic disease 7. Age ≥ 18 years 8. ECOG performance status ≤ 1 9. Measurable disease according to RECIST v1.1 outside any previously irradiated field. At least one site of disease must be unidimensionally ≥ 10 mm 10. Life expectancy &gt; 3 months 11. ≥ 1 previous line (s) of chemotherapy in the palliative setting 12. No symptomatic central nervous system disease 13. No chronic use of glucocorticoids 14. Adequate hematological, renal, metabolic and hepatic function: 1. Hemoglobin ≥ 9 g/dl (patients may have received prior red blood cell transfusion); ANC ≥ 1.5 x 109/l and platelet count ≥ 100 x 109/l, lymphocyte count ≥ 1.109 /l 2. ALT and AST ≤ 2.5 x upper limit of normality (ULN) (≤ 5 in case of liver metastasis) 3. Total bilirubin ≤ 1.5 x ULN OR Direct bilirubin ≤ ULN for subjects with total bilirubin levels ≥ 1.5 x ULN 4. Albumin ≥ 25g/l 5. Serum creatinine ≤ 1.5 x ULN OR CrCl ≥ 60 ml/min for subject with creatinine levels ≥ 1.5 x ULN, 6. Creatine phosphokinase ≤ 2.5 x ULN 7. INR ≤ 1.5 x ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants 8. aPTT ≤ 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants 15. No prior or concurrent malignant disease diagnosed or treated in the last 2 years except for adequately treated in situ carcinoma of the cervix, basal or squamous skin cell carcinoma, or in situ transitional bladder cell carcinoma, 16. At least three weeks since last chemotherapy, immunotherapy or any other pharmacological treatment and/or radiotherapy 17. Recovery to grade ≤ 1 from any adverse event from previous treatment (excluding alopecia of any grade and nonpainful peripheral neuropathy grade ≤ 2 (NCICTCAE, v 4.0) 18. Women of childbearing potential must have a negative serum pregnancy test within 72 hours prior to receiving the first dose of study medication. Both women and men must agree to use a medically acceptable method of contraception throughout the treatment period and for four months after discontinuation of treatment. Acceptable methods for contraception include intrauterine device, oral contraceptive, subdermal implant and double barrier. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for ≥ 1 year 19. Voluntary signed and dated written informed consents prior to any specific study procedure 20. Patients with a French social security in compliance with the Law relating to biomedical research (Article 112111 of French Public Health Code) 1. Previous treatment with MK3475 or CP 2. Has received prior therapy with an antiPD1, antiPDL1, antiPDL2, antiCD137, or antiCTLA4 antibody (including ipilimumab or any other antibody or drug specifically targeting Tcell costimulation or checkpoint pathways) 3. Evidence of progressive or symptomatic central nervous system (CNS) or leptomeningeal metastases 4. Men or women of childbearing potential who are not using an effective method of contraception as previously described; women who are pregnant or breast feeding 5. Participation to a study involving a medical or therapeutic intervention in the last 30 days 6. Previous enrolment in the present study 7. Patient unable to follow and comply with the study procedures because of any geographical, familial, social or psychological reasons 8. Known hypersensitivity to any involved study drug or of its formulation components 9. Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Subjects with hypothyroidism stable on hormone replacement or Sjorgen's syndrome will not be excluded from the study 10. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment 11. History of idiopathic pulmonary fibrosis (including pneumonitis), druginduced pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted 12. Has known active hepatitis B or hepatitis C 13. Has a known history of HIV (HIV1/2 antibodies), 14. Has received a live vaccine within 30 days prior to the first dose of trial treatment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Efficacy of MK 3475 with Metronomic Cyclophosphamide</keyword>
	<keyword>Advanced Sarcomas</keyword>
	<keyword>Leiomyosarcoma</keyword>
	<keyword>Undifferentiated Sarcoma</keyword>
	<keyword>Other Sarcoma</keyword>
	<keyword>GIST</keyword>
	<keyword>Osteosarcoma</keyword>
</DOC>